{"id":535480,"date":"2021-09-08T08:04:37","date_gmt":"2021-09-08T12:04:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/"},"modified":"2021-09-08T08:04:37","modified_gmt":"2021-09-08T12:04:37","slug":"vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/","title":{"rendered":"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference"},"content":{"rendered":"
\n

BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th<\/sup> – 15th<\/sup>.<\/p>\n

The presentation will take the form of a fireside chat, which will be available on demand here<\/a> beginning September 13th<\/sup> at 7:00 AM (ET) and archived for 90 days. Management will also be available for 1-on-1 meetings with investors.<\/p>\n\n\n\n\n
Date:<\/td>\nSeptember 13<\/td>\n<\/tr>\n
Time:<\/td>\nOn Demand, beginning at 7:00 AM (ET)<\/td>\n<\/tr>\n
Webcast:<\/td>\n\n VYNE Fireside Chat<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

For more information about the 23rd Annual Global Investment Conference, please visit the H.C. Wainwright conference website https:\/\/hcwevents.com\/annualconference\/<\/a><\/p>\n

\n About VYNE Therapeutics Inc.<\/strong>
\n
VYNE\u2019s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions.<\/p>\n

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of therapies for major immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company\u2019s unique and proprietary pipeline includes Phase 3 ready FCD105 (3% minocycline and 0.3% adapalene) for the treatment of moderate-to-severe acne vulgaris, FMX114 for the treatment of mild-to-moderate atopic dermatitis and a library of bromodomain & extra-terminal domain inhibitors in both topical and oral forms for the treatment of major immuno-inflammatory conditions and rare skin diseases. VYNE has received FDA approval for AMZEEQ\u00ae (minocycline) topical foam, 4%, the world\u2019s first topical minocycline, and for ZILXI\u00ae (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ\u2019s Full Prescribing Information at AMZEEQ.com<\/a> and ZILXI\u2019s Full Prescribing Information at ZILXI.com<\/a>.<\/p>\n

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com<\/a> or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE\u2019s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.<\/p>\n

\n Investor Relations:<\/strong>
\n
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com<\/a><\/p>\n

Tyler Zeronda
Chief Financial Officer
VYNE Therapeutics
908-458-9106
Tyler.Zeronda@vynetx.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th – 15th. The presentation will take the form of a fireside chat, which will be available on demand here beginning September 13th at 7:00 AM (ET) and archived for 90 days. Management will also be available for 1-on-1 meetings with investors. Date: September 13 Time: On Demand, beginning at 7:00 AM (ET) Webcast: VYNE Fireside Chat For more information about the 23rd Annual Global Investment Conference, please visit the H.C. Wainwright conference website https:\/\/hcwevents.com\/annualconference\/ About VYNE Therapeutics … <\/p>\n

Continue reading “VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535480","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th – 15th. The presentation will take the form of a fireside chat, which will be available on demand here beginning September 13th at 7:00 AM (ET) and archived for 90 days. Management will also be available for 1-on-1 meetings with investors. Date: September 13 Time: On Demand, beginning at 7:00 AM (ET) Webcast: VYNE Fireside Chat For more information about the 23rd Annual Global Investment Conference, please visit the H.C. Wainwright conference website https:\/\/hcwevents.com\/annualconference\/ About VYNE Therapeutics … Continue reading "VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:04:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference\",\"datePublished\":\"2021-09-08T12:04:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/\"},\"wordCount\":393,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/\",\"name\":\"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=\",\"datePublished\":\"2021-09-08T12:04:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference - Market Newsdesk","og_description":"BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th – 15th. The presentation will take the form of a fireside chat, which will be available on demand here beginning September 13th at 7:00 AM (ET) and archived for 90 days. Management will also be available for 1-on-1 meetings with investors. Date: September 13 Time: On Demand, beginning at 7:00 AM (ET) Webcast: VYNE Fireside Chat For more information about the 23rd Annual Global Investment Conference, please visit the H.C. Wainwright conference website https:\/\/hcwevents.com\/annualconference\/ About VYNE Therapeutics … Continue reading \"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:04:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference","datePublished":"2021-09-08T12:04:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/"},"wordCount":393,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/","name":"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=","datePublished":"2021-09-08T12:04:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTc3MCM0MzkzNDcxIzIwOTM4MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-h-c-wainwright-annual-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535480"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535480\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}